In a regulatory filing, Rapport Therapeutics (RAPP) disclosed that its director Steven Paul bought 41.7K shares of common stock on September 12th in a total transaction size of $1.03M.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RAPP: